Sacral neuromodulation (SNM) has, since the 1990s, effectively improved outcomes in patients suffering from genitourinary disorders. SNM is currently indicated by the FDA for disorders such as urinary frequency and urgency, urinary urgency incontinence, non-obstructive urinary retention, and fecal incontinence. Off-label, SNM may improve pelvic pain, interstitial cystitis, dyspareunia, pelvic floor dysfunction, chronic constipation, sexual dysfunction, and persistent genital arousal.
Neuromodulation is achieved by implanted electrical leads which stimulate sacral nerve roots. The first iterations of stimulator implants, developed in the 1990s, were not designed to be compatible with technology of today, namely MRI. Although current models of stimulator implants are MRI-compatible, a great number of patients still retain MRI-incompatible titanium leads which may heat up during magnetic imaging. For this reason, as well as lead migration, loss of efficacy, or adverse events, implanted leads may need to be removed.